




Form PTO-1449 (Rev. 2-32) U.S. Department of Commerce Patent & Trademark Office INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)				Atty. Docket No.: Q-61434		Serial No.: 09/674,377	
				Applicant: Toshikazu NAKAMURA			
				Filing Date: October 30, 2000		Group: 0000 Conf. No.: 0000	
U.S. PATENT DOCUMENTS							
Examiner Initial		Document Number	Date	Name	Class	Sub- Class	Filing Date (if appropriate)
							
FOREIGN PATENT DOCUMENTS							
		Document	Date	Country	Class	Sub- class	Translation Yes/No
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
		"Cancer Prevention and Therapy by HGF Antagonist", <i>Geka</i> (Surgery), <u>60(12)</u> :1637-1642 (1998) (Partial English Translation)					
		Date et al, <i>Oncogene</i> , <u>17</u> :3045-3054 (1998)					
		Matsumoto et al, <i>J. of Biol. Chem.</i> , <u>273(36)</u> :22913-22920 (1998)					
EXAMINER:				DATE CONSIDERED: <u>4/30/03</u>			
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication.							

RECEIVED

JAN 16 2003

TECH CENTER 1600/2900